iStockAnalyst.com (Free subscription) | 10/02/2009
On September 30, Teva Pharmaceutical Industries Ltd (TEVA), sold the worldwide rights to a generic version of the white blood-cell boosting drug filgrastim to Hospira Inc (NYSE:HSP). [More...]
Business Wire (Free subscription) | 08/11/2009
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today announced U.S. Food and Drug Administration (FDA) approval and launch of Oxaliplatin Injection. Teva’s 505(b)(2) New Drug
AdvancedTrading (Free subscription) | 08/07/2009
Teva Pharmaceutical Industries Ltd and Seneca Gaming Corp sued Merrill Lynch in separate lawsuits Thursday over investments in auction rate securities, a risky debt market that collapsed in early 2008.
Business Wire (Free subscription) | 08/05/2009
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Court of Appeals for the Federal Circuit has affirmed a ruling by the U.S. District Court for the District of
Radon Mitigation Pittsburgh (Free subscription) | 08/05/2009
(EMAILWIRE.COM, August 05, 2009 ) America's 78 million baby boomers are richer than any group in history; the group controls 50% of all U.S. discretionary income and accounts for 75% of drug spending. As an investor you cannot afford to ignore this demographic in the coming years and where they will be spending their retirement money. As more boomers approach retirement, forecasters expect a huge bump...
Business Wire (Free subscription) | 07/30/2009
EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NYSE Amex: AIS) today announced that it has received a payment from Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA), which will be applied to the design and
SeekingAlpha.com (Free subscription) | 07/28/2009
Zacks.com submits: On July 28, 2009, Teva Pharmaceutical Industries Ltd. ( TEVA ) reported financial results for the second quarter ended June 30, 2009. Net sales increased 20% y-o-y to $3.4 billion in the reported quarter, missing the consensus estimate by a small margin. The strengthening U.S. dollar adversely impacted net sales by $256 million or 9%. Non-GAAP net income increased 25% to $742 million....
Forex Analytics (Free subscription) | 07/28/2009
JERUSALEMde —-Teva Pharmaceutical Industries ltd today reported results for ended June quarter the 30, 2009. More: continued here (c)Autor: Forex Analytics Blog: earn money with Forex convert this post to pdf.Post from: (c)Autor: Forex Analytics Resultate of Teva Carryforward-Zweiten Quartal-2009 (Geschäfts-Draht) Post from: (c)Autor: Forex Analytics Resultate of Teva Carryforward-Zweiten...
Market Watch (Free subscription) | 07/28/2009
TEL AVIV (MarketWatch) -- Teva Pharmaceutical Industries Ltd., the Jerusalem drugmaker, reported that second-quarter net income fell 2.3%, and adjusted profit rose a stronger-than-expected 25%, on 20% higher sales. Earnings were $521 million, or 58 cents a share, compared with $533 million, or 65 cents, in the year-earlier quarter. Adjusted earnings in the latest period were $742 million, or 83 cents...
iStockAnalyst.com (Free subscription) | 07/25/2009
Teva Pharmaceutical Industries Ltd. is scheduled o report its second quarter earnings conference call before the market opens on Tuesday, July 28, 2009. Analysts currently expect the company to report earnings of 80 cents per share on revenue of $3.47 bi [More...]
IPBiz (Free subscription) | 07/24/2009
Reuters quoted &J spokesman Greg Panico: "This settlement compensates us for loss caused by their [Teva's] at-risk launch and recognizes the patent is valid and enforceable," suggesting that Teva was folding the tent on this Hatch-Waxman case [but see below]. Teva gets a license to re-enter the market on December 31, 2015, or earlier in certain circumstances, even though the patent does...
Business Wire (Free subscription) | 07/24/2009
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that it has entered into a definitive agreement with Ortho-McNeil-Janssen to settle the patent infringement lawsuit in the
Market Watch (Free subscription) | 07/17/2009
LOS ANGELES (MarketWatch) -- Teva Pharmaceutical Industries Ltd. said Friday that it and Ortho McNeil Janssen have extended their agreement to cease shipments of generic versions of birth-control pill Ortho Tri-Cyclen Lo. The shipments will be ceased until a court ruling on a motion of preliminary injunction in related patent infringement case or until July 29, depending upon which event arrives first....
Market Watch (Free subscription) | 07/17/2009
LOS ANGELES (MarketWatch) -- The U.S. Food and Drug Administration said Friday that Teva Pharmaceuticals USA, a subsidiary of Teva Pharmaceutical Industries Ltd. , has issued a voluntary, nationwide recall of certain lots of Propofol because of the presence of elevated endotoxin levels in some vials of the injectable, general anesthesia drug. Teva has been notified that 41 patients treated with Propofol...
Times of the Internet (Free subscription) | 07/16/2009
COLUMBUS, Ohio, July 15 (UPI) -- Women theoretically understand menopause, but many underestimate the symptoms and their impact physically and emotionally, U.S. researchers said. Principal investigator David Portman of the Columbus Center for Women's Health Research in Ohio said 87 percent of women experience anxiety, depression and mood swings, and these symptoms negatively impact their relationships,...
Videos